LUND, Sweden, April 1, 2022 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced the
completion of the patient enrollment for the 600 mg dose cohort
from Alligator's Phase I, first-in-human clinical trial with
the 4-1BB (CD137) targeting drug candidate, ATOR-1017, which is
being developed as a tumor-directed therapy for
advanced/metastatic cancer. The Phase I study with ATOR-1017 is
an open-label, dose escalation study in patients with
histologically confirmed, advanced and/or refractory solid cancer
(NCT04144842). The primary objective of the study is to investigate
the safety and tolerability of ATOR-1017, and to determine the
recommended dose for subsequent Phase II studies.
The data indicate that for doses up to 600 mg, there were no
significant safety concerns with stable disease as the best tumor
response. Patient enrollment and treatment for the highest planned
dose cohort, 900 mg, has commenced.
As previously announced in December
2021, results from the early readout for ATOR-1017 showed
that the drug candidate has an encouraging safety profile. In this
readout, there was no dose-limiting toxicity or severe
immune-related adverse events (link to press release).
For further information, please contact:
Julie Silber, Investor
Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets mitazalimab, a
CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore,
Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics
Inc., several undisclosed molecules based on its proprietary
technology platform, Neo-X-Prime™, and novel drug candidates based
on the RUBY™ bispecific platform with Orion Corporation. Out
licensed programs include AC101, in phase II development, by
Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus
Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm
(ATORX) and is headquartered in Lund,
Sweden.
For more information, please
visit http://www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-announces-completion-of-600-mg-dose-cohort-for-ator-1017--dose-escalation-and-e,c3537725
The following files are available for download:
|
https://mb.cision.com/Main/12681/3537725/1557924.pdf
|
Alligator ATOR 1017 Q1
press release ENG FINAL
|
